A Phase 1 interventional study of Belumosudil mesylate and Placebo in Immune System Disorder (Healthy Volunteer), sponsored by Kadmon, a Sanofi Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-26.
Sponsored by Kadmon, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple oral doses and regimens of KD025 in healthy male and post-menopausal female participants.
Up to approximately 37 days including safety follow up period of 30 days after participant is treated with the last dose of study drug.
428 studies on the registry are indexed under Immune System Diseases; 87 are open to participants now.
This study's enrollment of 32 is below the median of 66 across 317 interventional studies indexed under Immune System Diseases.
Browse Immune System Diseases studies →Kadmon, a Sanofi Company is the lead sponsor of 14 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
First submitted after Kadmon Corporation, LLC became part of Sanofi.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 mg KD025 or placebo once daily (QD) for 7 days
Drug: Belumosudil mesylate · Drug: Placebo
800 mg KD025 or placebo QD for 7 days
Drug: Belumosudil mesylate · Drug: Placebo
500 mg KD025 or placebo twice daily (BID) for 7 days
Drug: Belumosudil mesylate · Drug: Placebo
1000 mg KD025 or placebo QD for 7 days
Drug: Belumosudil mesylate · Drug: Placebo
Pharmaceutical form: capsule; Route of administration: oral
Also known as: KD025, SAR445761
Pharmaceutical form: capsule; Route of administration: oral
Number of participants with adverse events and serious adverse events
Safety observations and measurements include AEs, safety laboratory tests, vital sign measurements, physical examinations, and ECGs.
Time frame: Up to approximately 37 days
Cmax of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)]
Cmax is maximum plasma concentration determined directly from the concentration time profile
Time frame: Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7
tmax of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)]
tmax is observed time to reach peak plasma concentration
Time frame: Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7
AUC0-24 of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)]
AUC0-24 is area under the plasma concentration-time curve from predose (time 0) to 24 hours Postdose
Time frame: Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7
AUCinf of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)]
AUCinf is area under the concentration-time curve from predose (time 0) extrapolated to Infinity
Time frame: Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7
Cmin of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)]
Cmin is minimum or "trough" plasma concentration after its administration and just prior to the administration of a subsequent dose as determined from the concentration time profile
Time frame: Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7
t1/2 of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)]
t1/2 is terminal elimination half-life
Time frame: Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Ran from Nov 2013 to primary completion in Mar 2014, 3 months.
Of 25 industry-sponsored phase 1 interventional studies under Immune System Diseases, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 32. This study's 3 months is below that.
Counting every sponsor, half of 39 studies reached it within 29 months; a quarter within 5 and three quarters within 69.
Immune System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belumosudil